In one of the first studies in which GLP-1 was tested on IBD, it was shown that the human GLP-1 (7-36) self-associated with PEGylated phospholipid micelles (GLP-1-SSM) partially reduced the diarrhoeal phenotype in mice with DSS colitis through two potential mechanisms: reduction in colonic inflammation and preservation of DRA (down-regulated in adenoma) expression. Here, GLP1R is linked to inflammatory bowel disease.